查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1239542

創傷性腦損傷(TBI)評估市場:按用戶,診斷類型(CT掃描,MRI,顱內壓監測,腦組織氧張力):全球機會分析行業預測,2021-2031

Traumatic brain injuries assessment Market By End-user, By Diagnostic Type (CT-Scan, MRI, Intracranial Pressure Monitoring, Partial Pressure of Oxygen in Brain Tissue, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 250 Pages | 商品交期: 2-3個工作天內

價格

到 2021 年，全球腦外傷 (TBI) 評估市場價值將達到 95.7 億美元，預計到 2031 年將產生 183.736 億美元的收入，複合年增長率為 7.0%。

創傷性腦損傷 (TBI) 評估市場的增長是印度的一個重大公共衛生問題。 創傷性腦損傷導致活躍的年輕成年人死亡、受傷和殘疾。 印度因 TBI 遭受了無法量化的巨大經濟損失。 在印度，TBI 預計會隨著汽車的普及和城市化進程的加快而增加。 世界衛生組織 (WHO) 最近發布的《道路交通傷害預防、暴力與健康全球報告》強調了世界各地傷害問題的嚴重程度以及如何實施預防、管理和康復計劃。它明確了需要做什麼緊急設計和評估。 印度是預防不是優先事項的國家之一。

TBI 會對執行功能和自我控制產生不利影響。 控制與壓力和焦慮相關的行為的能力稱為自我調節。 患有 TBI 的人可能會發現很難保持冷靜，很難等待輪到他們，並且在陌生的環境中會情緒高漲。 執行功能是指涉及計劃、記憶、目標設定、注意力和服從指令的高級大腦功能。 由於患有 TBI 的人很容易混淆和健忘，因此學習新信息、完成文書工作和使用公共交通工具可能很困難。

市場進入者採用最新技術和推出新產品預計將在預測期內加速市場擴張。 例如，BioDirection, Inc. 的 NanoDx 系統是一種快速即時 (POC) 診斷，可在不到兩分鐘的時間內準確診斷出腦震盪/TBI。

雖然這項由國家殘疾、獨立生活和康復研究所 (NIDILRR) 資助的研究仍在進行中，但初步研究結果表明，這種流行病已經影響社會隔離、日常生活中斷、認知能力。對腦損傷患者產生重大影響，包括對 由社區服務辦公室資助的創傷性腦損傷技術援助和資源中心 (TBI TARC) 已著手進一步調查 COVID-19 如何影響腦損傷患者。 TBI 諮詢領導 (TAL) 小組的五名成員接受了 TBI TARC 的質詢。 TAL 組的目的是規定 TBI TARC 的優先級。

內容

第 1 章介紹

第 2 章執行摘要

第 3 章市場概述

  • 市場定義和範圍
  • 主要發現
    • 主要投資領域
  • 波特的五力分析
  • 市場動態
    • 促進因素
    • 約束因素
    • 機會
  • 分析 COVID-19 對市場的影響
  • 價值鏈分析
  • 主要監管分析
  • 專利情況
  • 監管準則
  • 市場份額分析

第 4 章創傷性腦損傷 (TBI) 評估市場：按最終用戶分類

  • 概覽
    • 市場規模和預測
  • 醫院
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 診斷中心
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 其他
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 5 章創傷性腦損傷 (TBI) 評估市場：按診斷類型

  • 概覽
    • 市場規模和預測
  • CT掃描
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 核磁共振
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 顱內壓監測
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 腦組織氧分壓 (pBrO2)
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 其他
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 6 章創傷性腦損傷 (TBI) 評估市場：按地區

  • 概覽
    • 市場規模和預測
  • 北美
    • 主要趨勢和機會
    • 北美市場規模和預測：按最終用戶分類
    • 北美市場規模和按診斷類型預測
    • 北美市場規模和預測：按國家/地區分類
      • 美國
      • 主要市場趨勢、增長動力和機遇
      • 最終用戶的市場規模和預測
      • 按診斷類型劃分的市場規模和預測
      • 加拿大
      • 主要市場趨勢、增長動力和機遇
      • 最終用戶的市場規模和預測
      • 按診斷類型劃分的市場規模和預測
      • 墨西哥
      • 主要市場趨勢、增長動力和機遇
      • 最終用戶的市場規模和預測
      • 按診斷類型劃分的市場規模和預測
  • 歐洲
    • 主要趨勢和機會
    • 歐洲市場規模和預測：按最終用戶分類
    • 歐洲市場規模和按診斷類型預測
    • 歐洲市場規模和預測：按國家/地區分類
      • 德國
      • 主要市場趨勢、增長動力和機遇
      • 最終用戶的市場規模和預測
      • 按診斷類型劃分的市場規模和預測
      • 英國
      • 主要市場趨勢、增長動力和機遇
      • 最終用戶的市場規模和預測
      • 按診斷類型劃分的市場規模和預測
      • 法國
      • 主要市場趨勢、增長動力和機遇
      • 最終用戶的市場規模和預測
      • 按診斷類型劃分的市場規模和預測
      • 西班牙
      • 主要市場趨勢、增長動力和機遇
      • 最終用戶的市場規模和預測
      • 按診斷類型劃分的市場規模和預測
      • 意大利
      • 主要市場趨勢、增長動力和機遇
      • 最終用戶的市場規模和預測
      • 按診斷類型劃分的市場規模和預測
      • 其他歐洲
      • 主要市場趨勢、增長動力和機遇
      • 最終用戶的市場規模和預測
      • 按診斷類型劃分的市場規模和預測
  • 亞太地區
    • 主要趨勢和機會
    • 亞太市場規模和預測：按最終用戶分類
    • 亞太市場規模和預測：按診斷類型
    • 亞太市場規模和預測：按國家/地區分類
      • 中國
      • 主要市場趨勢、增長動力和機遇
      • 最終用戶的市場規模和預測
      • 按診斷類型劃分的市場規模和預測
      • 日本
      • 主要市場趨勢、增長動力和機遇
      • 最終用戶的市場規模和預測
      • 按診斷類型劃分的市場規模和預測
      • 印度
      • 主要市場趨勢、增長動力和機遇
      • 最終用戶的市場規模和預測
      • 按診斷類型劃分的市場規模和預測
      • 韓國
      • 主要市場趨勢、增長動力和機遇
      • 最終用戶的市場規模和預測
      • 按診斷類型劃分的市場規模和預測
      • 澳大利亞
      • 主要市場趨勢、增長動力和機遇
      • 最終用戶的市場規模和預測
      • 按診斷類型劃分的市場規模和預測
      • 其他亞太地區
      • 主要市場趨勢、增長動力和機遇
      • 最終用戶的市場規模和預測
      • 按診斷類型劃分的市場規模和預測
  • 拉丁美洲/中東/非洲
    • 主要趨勢和機會
    • LAMEA 市場規模和預測：按最終用戶分類
    • LAMEA 市場規模和按診斷類型預測
    • LAMEA 市場規模和預測：按國家/地區分類
      • 巴西
      • 主要市場趨勢、增長動力和機遇
      • 最終用戶的市場規模和預測
      • 按診斷類型劃分的市場規模和預測
      • 沙特阿拉伯
      • 主要市場趨勢、增長動力和機遇
      • 最終用戶的市場規模和預測
      • 按診斷類型劃分的市場規模和預測
      • 阿拉伯聯合酋長國
      • 主要市場趨勢、增長動力和機遇
      • 最終用戶的市場規模和預測
      • 按診斷類型劃分的市場規模和預測
      • 南非
      • 主要市場趨勢、增長動力和機遇
      • 最終用戶的市場規模和預測
      • 按診斷類型劃分的市場規模和預測
      • 其他拉丁美洲/中東/非洲
      • 主要市場趨勢、增長動力和機遇
      • 最終用戶的市場規模和預測
      • 按診斷類型劃分的市場規模和預測

第 7 章競爭格局

  • 介紹
  • 關鍵成功策略
  • 排名前 10 位的玩家產品映射
  • 比賽儀表板
  • 競爭熱圖
  • 2021 年最佳球員排名

第 8 章公司簡介

  • brainscope company inc.
  • NOVASIGNAL CORPORATION
  • Integra LifeSciences Holdings Corporation
  • Natus Medical Incorporated
  • Boston Scientific Corporation
  • Koninklijke Philips N.V.
  • BioDirection, Inc.
  • Nihon Kohden Corp.
  • RAUMEDIC AG
  • Compumedics Ltd.
Product Code: A31382

The global traumatic brain injuries assessment market size was $9,570 million in 2021 and is predicted to expand at a CAGR of 7.0% % by generating a revenue of $18,373.6 million by 2031.

Traumatic brain injuries assessment market growth is a significant public health issue in India. They contribute to the demise, harm, and disabling of young, active members of society. India suffers huge economic losses due to TBIs, yet they are unquantifiable. TBIs will rise in India as it moves toward greater growth and development in terms of motorization and urbanization. The World Health Organization's recent world reports on road traffic injury prevention and violence &health make clear how serious the problem of injuries is getting around the world and how urgently programs for prevention, management, and rehabilitation need to be designed and evaluated. India is one nation that has not prioritized prevention.

TBIs negatively affect executive function and self-control. The ability to control stress- and anxiety-related behavior is known as self-regulation. For someone with a TBI, this can involve difficulty settling down, difficulty waiting their turn, or having overpowering emotions in strange settings. Executive functioning refers to higher-order brain functions that are involved in planning, recalling, setting goals, focusing attention, and obeying directions. TBI sufferers may easily become disoriented or forget things, and they may find it challenging to learn new information, complete paperwork, or use public transportation.

The adoption of the most recent technologies and the launch of new products by market participants are expected to accelerate market expansion during the forecast period. For instance, Bio Direction, Inc.'s NanoDx system is a quick point-of-care (POC) diagnostic that accurately diagnoses concussions/TBIs in under two minutes.

The study, which is being funded by the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR), is still in progress, but preliminary findings indicate that the pandemic has a significant impact on those who have had brain injuries, including social isolation, disruption of daily life, and effects on cognition. The Administration for Community Living-funded Traumatic Brain Damage Technical Assistance and Resource Center (TBI TARC) set out to further study how COVID-19 has affected people with brain injuries. The TBI Advisory and Leadership (TAL) group's five members were questioned by the TBI TARC. The TAL group's goal is to direct TBI TARC's priorities.

The key players profiled in this report include: Integra Lifesciences, BioDirection, Inc., Nihon Kohden Corp., Compumedics Ltd., InfraScan, Inc., Oculogica, Raumedic AG, Zagros Petrochemical Co., Koninklijke Philips N.V, Boston Scientific Corporation, and Elekta.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the traumatic brain injuries assessment market analysis from 2021 to 2031 to identify the prevailing traumatic brain injuries assessment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the traumatic brain injuries assessment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global traumatic brain injuries assessment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By End-user

  • Hospital
  • Diagnostics Center
  • Others

By Diagnostic Type

  • CT-Scan
  • MRI
  • Intracranial Pressure Monitoring
  • Partial Pressure of Oxygen in Brain Tissue (pBrO2)
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • UAE
    • South Africa
    • Rest of LAMEA

Key Market Players

  • brainscope company inc.
  • NOVASIGNAL CORPORATION
  • Integra LifeSciences Holdings Corporation
  • Natus Medical Incorporated
  • Boston Scientific Corporation
  • Koninklijke Philips N.V.
  • BioDirection, Inc.
  • Nihon Kohden Corp.
  • RAUMEDIC AG
  • Compumedics Ltd.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Market dynamics
    • 3.4.1.Drivers
    • 3.4.2.Restraints
    • 3.4.3.Opportunities
  • 3.5.COVID-19 Impact Analysis on the market
  • 3.6.Value Chain Analysis
  • 3.7.Key Regulation Analysis
  • 3.8.Patent Landscape
  • 3.9.Regulatory Guidelines
  • 3.10.Market Share Analysis

CHAPTER 4: TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2. Hospital
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market share analysis by country
  • 4.3. Diagnostics Center
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market share analysis by country
  • 4.4. Others
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market share analysis by country

CHAPTER 5: TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2. CT-Scan
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market share analysis by country
  • 5.3. MRI
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market share analysis by country
  • 5.4. Intracranial Pressure Monitoring
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market share analysis by country
  • 5.5. Partial Pressure of Oxygen in Brain Tissue (pBrO2)
    • 5.5.1 Key market trends, growth factors and opportunities
    • 5.5.2 Market size and forecast, by region
    • 5.5.3 Market share analysis by country
  • 5.6. Others
    • 5.6.1 Key market trends, growth factors and opportunities
    • 5.6.2 Market size and forecast, by region
    • 5.6.3 Market share analysis by country

CHAPTER 6: TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY REGION

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 North America
    • 6.2.1 Key trends and opportunities
    • 6.2.2 North America Market size and forecast, by End-user
    • 6.2.3 North America Market size and forecast, by Diagnostic Type
    • 6.2.4 North America Market size and forecast, by country
      • 6.2.4.1 U.S.
      • 6.2.4.1.1 Key market trends, growth factors and opportunities
      • 6.2.4.1.2 Market size and forecast, by End-user
      • 6.2.4.1.3 Market size and forecast, by Diagnostic Type
      • 6.2.4.2 Canada
      • 6.2.4.2.1 Key market trends, growth factors and opportunities
      • 6.2.4.2.2 Market size and forecast, by End-user
      • 6.2.4.2.3 Market size and forecast, by Diagnostic Type
      • 6.2.4.3 Mexico
      • 6.2.4.3.1 Key market trends, growth factors and opportunities
      • 6.2.4.3.2 Market size and forecast, by End-user
      • 6.2.4.3.3 Market size and forecast, by Diagnostic Type
  • 6.3 Europe
    • 6.3.1 Key trends and opportunities
    • 6.3.2 Europe Market size and forecast, by End-user
    • 6.3.3 Europe Market size and forecast, by Diagnostic Type
    • 6.3.4 Europe Market size and forecast, by country
      • 6.3.4.1 Germany
      • 6.3.4.1.1 Key market trends, growth factors and opportunities
      • 6.3.4.1.2 Market size and forecast, by End-user
      • 6.3.4.1.3 Market size and forecast, by Diagnostic Type
      • 6.3.4.2 UK
      • 6.3.4.2.1 Key market trends, growth factors and opportunities
      • 6.3.4.2.2 Market size and forecast, by End-user
      • 6.3.4.2.3 Market size and forecast, by Diagnostic Type
      • 6.3.4.3 France
      • 6.3.4.3.1 Key market trends, growth factors and opportunities
      • 6.3.4.3.2 Market size and forecast, by End-user
      • 6.3.4.3.3 Market size and forecast, by Diagnostic Type
      • 6.3.4.4 Spain
      • 6.3.4.4.1 Key market trends, growth factors and opportunities
      • 6.3.4.4.2 Market size and forecast, by End-user
      • 6.3.4.4.3 Market size and forecast, by Diagnostic Type
      • 6.3.4.5 Italy
      • 6.3.4.5.1 Key market trends, growth factors and opportunities
      • 6.3.4.5.2 Market size and forecast, by End-user
      • 6.3.4.5.3 Market size and forecast, by Diagnostic Type
      • 6.3.4.6 Rest of Europe
      • 6.3.4.6.1 Key market trends, growth factors and opportunities
      • 6.3.4.6.2 Market size and forecast, by End-user
      • 6.3.4.6.3 Market size and forecast, by Diagnostic Type
  • 6.4 Asia-Pacific
    • 6.4.1 Key trends and opportunities
    • 6.4.2 Asia-Pacific Market size and forecast, by End-user
    • 6.4.3 Asia-Pacific Market size and forecast, by Diagnostic Type
    • 6.4.4 Asia-Pacific Market size and forecast, by country
      • 6.4.4.1 China
      • 6.4.4.1.1 Key market trends, growth factors and opportunities
      • 6.4.4.1.2 Market size and forecast, by End-user
      • 6.4.4.1.3 Market size and forecast, by Diagnostic Type
      • 6.4.4.2 Japan
      • 6.4.4.2.1 Key market trends, growth factors and opportunities
      • 6.4.4.2.2 Market size and forecast, by End-user
      • 6.4.4.2.3 Market size and forecast, by Diagnostic Type
      • 6.4.4.3 India
      • 6.4.4.3.1 Key market trends, growth factors and opportunities
      • 6.4.4.3.2 Market size and forecast, by End-user
      • 6.4.4.3.3 Market size and forecast, by Diagnostic Type
      • 6.4.4.4 South Korea
      • 6.4.4.4.1 Key market trends, growth factors and opportunities
      • 6.4.4.4.2 Market size and forecast, by End-user
      • 6.4.4.4.3 Market size and forecast, by Diagnostic Type
      • 6.4.4.5 Australia
      • 6.4.4.5.1 Key market trends, growth factors and opportunities
      • 6.4.4.5.2 Market size and forecast, by End-user
      • 6.4.4.5.3 Market size and forecast, by Diagnostic Type
      • 6.4.4.6 Rest of Asia-Pacific
      • 6.4.4.6.1 Key market trends, growth factors and opportunities
      • 6.4.4.6.2 Market size and forecast, by End-user
      • 6.4.4.6.3 Market size and forecast, by Diagnostic Type
  • 6.5 LAMEA
    • 6.5.1 Key trends and opportunities
    • 6.5.2 LAMEA Market size and forecast, by End-user
    • 6.5.3 LAMEA Market size and forecast, by Diagnostic Type
    • 6.5.4 LAMEA Market size and forecast, by country
      • 6.5.4.1 Brazil
      • 6.5.4.1.1 Key market trends, growth factors and opportunities
      • 6.5.4.1.2 Market size and forecast, by End-user
      • 6.5.4.1.3 Market size and forecast, by Diagnostic Type
      • 6.5.4.2 Saudi Arabia
      • 6.5.4.2.1 Key market trends, growth factors and opportunities
      • 6.5.4.2.2 Market size and forecast, by End-user
      • 6.5.4.2.3 Market size and forecast, by Diagnostic Type
      • 6.5.4.3 UAE
      • 6.5.4.3.1 Key market trends, growth factors and opportunities
      • 6.5.4.3.2 Market size and forecast, by End-user
      • 6.5.4.3.3 Market size and forecast, by Diagnostic Type
      • 6.5.4.4 South Africa
      • 6.5.4.4.1 Key market trends, growth factors and opportunities
      • 6.5.4.4.2 Market size and forecast, by End-user
      • 6.5.4.4.3 Market size and forecast, by Diagnostic Type
      • 6.5.4.5 Rest of LAMEA
      • 6.5.4.5.1 Key market trends, growth factors and opportunities
      • 6.5.4.5.2 Market size and forecast, by End-user
      • 6.5.4.5.3 Market size and forecast, by Diagnostic Type

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top player positioning, 2021

CHAPTER 8: COMPANY PROFILES

  • 8.1 brainscope company inc.
    • 8.1.1 Company overview
    • 8.1.2 Key Executives
    • 8.1.3 Company snapshot
    • 8.1.4 Operating business segments
    • 8.1.5 Product portfolio
    • 8.1.6 Business performance
    • 8.1.7 Key strategic moves and developments
  • 8.2 NOVASIGNAL CORPORATION
    • 8.2.1 Company overview
    • 8.2.2 Key Executives
    • 8.2.3 Company snapshot
    • 8.2.4 Operating business segments
    • 8.2.5 Product portfolio
    • 8.2.6 Business performance
    • 8.2.7 Key strategic moves and developments
  • 8.3 Integra LifeSciences Holdings Corporation
    • 8.3.1 Company overview
    • 8.3.2 Key Executives
    • 8.3.3 Company snapshot
    • 8.3.4 Operating business segments
    • 8.3.5 Product portfolio
    • 8.3.6 Business performance
    • 8.3.7 Key strategic moves and developments
  • 8.4 Natus Medical Incorporated
    • 8.4.1 Company overview
    • 8.4.2 Key Executives
    • 8.4.3 Company snapshot
    • 8.4.4 Operating business segments
    • 8.4.5 Product portfolio
    • 8.4.6 Business performance
    • 8.4.7 Key strategic moves and developments
  • 8.5 Boston Scientific Corporation
    • 8.5.1 Company overview
    • 8.5.2 Key Executives
    • 8.5.3 Company snapshot
    • 8.5.4 Operating business segments
    • 8.5.5 Product portfolio
    • 8.5.6 Business performance
    • 8.5.7 Key strategic moves and developments
  • 8.6 Koninklijke Philips N.V.
    • 8.6.1 Company overview
    • 8.6.2 Key Executives
    • 8.6.3 Company snapshot
    • 8.6.4 Operating business segments
    • 8.6.5 Product portfolio
    • 8.6.6 Business performance
    • 8.6.7 Key strategic moves and developments
  • 8.7 BioDirection, Inc.
    • 8.7.1 Company overview
    • 8.7.2 Key Executives
    • 8.7.3 Company snapshot
    • 8.7.4 Operating business segments
    • 8.7.5 Product portfolio
    • 8.7.6 Business performance
    • 8.7.7 Key strategic moves and developments
  • 8.8 Nihon Kohden Corp.
    • 8.8.1 Company overview
    • 8.8.2 Key Executives
    • 8.8.3 Company snapshot
    • 8.8.4 Operating business segments
    • 8.8.5 Product portfolio
    • 8.8.6 Business performance
    • 8.8.7 Key strategic moves and developments
  • 8.9 RAUMEDIC AG
    • 8.9.1 Company overview
    • 8.9.2 Key Executives
    • 8.9.3 Company snapshot
    • 8.9.4 Operating business segments
    • 8.9.5 Product portfolio
    • 8.9.6 Business performance
    • 8.9.7 Key strategic moves and developments
  • 8.10 Compumedics Ltd.
    • 8.10.1 Company overview
    • 8.10.2 Key Executives
    • 8.10.3 Company snapshot
    • 8.10.4 Operating business segments
    • 8.10.5 Product portfolio
    • 8.10.6 Business performance
    • 8.10.7 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 2. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET FOR HOSPITAL, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 3. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET FOR DIAGNOSTICS CENTER, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 4. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 5. GLOBAL TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 6. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET FOR CT-SCAN, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 7. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET FOR MRI, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 8. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET FOR INTRACRANIAL PRESSURE MONITORING, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 9. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET FOR PARTIAL PRESSURE OF OXYGEN IN BRAIN TISSUE (PBRO2), BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. NORTH AMERICA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. NORTH AMERICA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. NORTH AMERICA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. U.S. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. U.S. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. CANADA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. CANADA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. MEXICO TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. MEXICO TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. EUROPE TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. EUROPE TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. EUROPE TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. GERMANY TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. GERMANY TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. UK TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. UK TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. FRANCE TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. FRANCE TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. SPAIN TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. SPAIN TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. ITALY TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. ITALY TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. REST OF EUROPE TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. REST OF EUROPE TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. ASIA-PACIFIC TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. ASIA-PACIFIC TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. ASIA-PACIFIC TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. CHINA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. CHINA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. JAPAN TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. JAPAN TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. INDIA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. INDIA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. SOUTH KOREA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. SOUTH KOREA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. AUSTRALIA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. AUSTRALIA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. REST OF ASIA-PACIFIC TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. REST OF ASIA-PACIFIC TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. LAMEA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. LAMEA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. LAMEA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. BRAZIL TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. BRAZIL TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. SAUDI ARABIA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. SAUDI ARABIA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. UAE TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. UAE TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. SOUTH AFRICA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. SOUTH AFRICA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 62. REST OF LAMEA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY END-USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 63. REST OF LAMEA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, BY DIAGNOSTIC TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 64. BRAINSCOPE COMPANY INC.: KEY EXECUTIVES
  • TABLE 65. BRAINSCOPE COMPANY INC.: COMPANY SNAPSHOT
  • TABLE 66. BRAINSCOPE COMPANY INC.: OPERATING SEGMENTS
  • TABLE 67. BRAINSCOPE COMPANY INC.: PRODUCT PORTFOLIO
  • TABLE 68. BRAINSCOPE COMPANY INC.: NET SALES
  • TABLE 69. BRAINSCOPE COMPANY INC.: KEY STRATERGIES
  • TABLE 70. NOVASIGNAL CORPORATION: KEY EXECUTIVES
  • TABLE 71. NOVASIGNAL CORPORATION: COMPANY SNAPSHOT
  • TABLE 72. NOVASIGNAL CORPORATION: OPERATING SEGMENTS
  • TABLE 73. NOVASIGNAL CORPORATION: PRODUCT PORTFOLIO
  • TABLE 74. NOVASIGNAL CORPORATION: NET SALES
  • TABLE 75. NOVASIGNAL CORPORATION: KEY STRATERGIES
  • TABLE 76. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: KEY EXECUTIVES
  • TABLE 77. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: COMPANY SNAPSHOT
  • TABLE 78. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: OPERATING SEGMENTS
  • TABLE 79. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: PRODUCT PORTFOLIO
  • TABLE 80. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: NET SALES
  • TABLE 81. INTEGRA LIFESCIENCES HOLDINGS CORPORATION: KEY STRATERGIES
  • TABLE 82. NATUS MEDICAL INCORPORATED: KEY EXECUTIVES
  • TABLE 83. NATUS MEDICAL INCORPORATED: COMPANY SNAPSHOT
  • TABLE 84. NATUS MEDICAL INCORPORATED: OPERATING SEGMENTS
  • TABLE 85. NATUS MEDICAL INCORPORATED: PRODUCT PORTFOLIO
  • TABLE 86. NATUS MEDICAL INCORPORATED: NET SALES
  • TABLE 87. NATUS MEDICAL INCORPORATED: KEY STRATERGIES
  • TABLE 88. BOSTON SCIENTIFIC CORPORATION: KEY EXECUTIVES
  • TABLE 89. BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
  • TABLE 90. BOSTON SCIENTIFIC CORPORATION: OPERATING SEGMENTS
  • TABLE 91. BOSTON SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
  • TABLE 92. BOSTON SCIENTIFIC CORPORATION: NET SALES
  • TABLE 93. BOSTON SCIENTIFIC CORPORATION: KEY STRATERGIES
  • TABLE 94. KONINKLIJKE PHILIPS N.V.: KEY EXECUTIVES
  • TABLE 95. KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT
  • TABLE 96. KONINKLIJKE PHILIPS N.V.: OPERATING SEGMENTS
  • TABLE 97. KONINKLIJKE PHILIPS N.V.: PRODUCT PORTFOLIO
  • TABLE 98. KONINKLIJKE PHILIPS N.V.: NET SALES
  • TABLE 99. KONINKLIJKE PHILIPS N.V.: KEY STRATERGIES
  • TABLE 100. BIODIRECTION, INC.: KEY EXECUTIVES
  • TABLE 101. BIODIRECTION, INC.: COMPANY SNAPSHOT
  • TABLE 102. BIODIRECTION, INC.: OPERATING SEGMENTS
  • TABLE 103. BIODIRECTION, INC.: PRODUCT PORTFOLIO
  • TABLE 104. BIODIRECTION, INC.: NET SALES
  • TABLE 105. BIODIRECTION, INC.: KEY STRATERGIES
  • TABLE 106. NIHON KOHDEN CORP.: KEY EXECUTIVES
  • TABLE 107. NIHON KOHDEN CORP.: COMPANY SNAPSHOT
  • TABLE 108. NIHON KOHDEN CORP.: OPERATING SEGMENTS
  • TABLE 109. NIHON KOHDEN CORP.: PRODUCT PORTFOLIO
  • TABLE 110. NIHON KOHDEN CORP.: NET SALES
  • TABLE 111. NIHON KOHDEN CORP.: KEY STRATERGIES
  • TABLE 112. RAUMEDIC AG: KEY EXECUTIVES
  • TABLE 113. RAUMEDIC AG: COMPANY SNAPSHOT
  • TABLE 114. RAUMEDIC AG: OPERATING SEGMENTS
  • TABLE 115. RAUMEDIC AG: PRODUCT PORTFOLIO
  • TABLE 116. RAUMEDIC AG: NET SALES
  • TABLE 117. RAUMEDIC AG: KEY STRATERGIES
  • TABLE 118. COMPUMEDICS LTD.: KEY EXECUTIVES
  • TABLE 119. COMPUMEDICS LTD.: COMPANY SNAPSHOT
  • TABLE 120. COMPUMEDICS LTD.: OPERATING SEGMENTS
  • TABLE 121. COMPUMEDICS LTD.: PRODUCT PORTFOLIO
  • TABLE 122. COMPUMEDICS LTD.: NET SALES
  • TABLE 123. COMPUMEDICS LTD.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1. SEGMENTATION OF TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031
  • FIGURE 2. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031
  • FIGURE 3. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 4. PORTER FIVE-1
  • FIGURE 5. PORTER FIVE-2
  • FIGURE 6. PORTER FIVE-3
  • FIGURE 7. PORTER FIVE-4
  • FIGURE 8. PORTER FIVE-5
  • FIGURE 9. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 10. VALUE CHAIN ANALYSIS
  • FIGURE 11. KEY REGULATION ANALYSIS
  • FIGURE 12. PATENT ANALYSIS BY COMPANY
  • FIGURE 13. PATENT ANALYSIS BY COUNTRY
  • FIGURE 14. REGULATORY GUIDELINES
  • FIGURE 15. MARKET SHARE ANALYSIS
  • FIGURE 16. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,BY END-USER,2021(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF HOSPITAL TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, 2021 AND 2031(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF DIAGNOSTICS CENTER TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, 2021 AND 2031(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF OTHERS TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, 2021 AND 2031(%)
  • FIGURE 20. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,BY DIAGNOSTIC TYPE,2021(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF CT-SCAN TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, 2021 AND 2031(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF MRI TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, 2021 AND 2031(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF INTRACRANIAL PRESSURE MONITORING TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, 2021 AND 2031(%)
  • FIGURE 24. COMPARATIVE SHARE ANALYSIS OF PARTIAL PRESSURE OF OXYGEN IN BRAIN TISSUE (PBRO2) TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, 2021 AND 2031(%)
  • FIGURE 25. COMPARATIVE SHARE ANALYSIS OF OTHERS TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET, 2021 AND 2031(%)
  • FIGURE 26. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET BY REGION,2021
  • FIGURE 27. U.S. TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 28. CANADA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 29. MEXICO TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 30. GERMANY TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 31. UK TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 32. FRANCE TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 33. SPAIN TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 34. ITALY TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 35. REST OF EUROPE TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 36. CHINA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 37. JAPAN TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 38. INDIA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 39. SOUTH KOREA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 40. AUSTRALIA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 41. REST OF ASIA-PACIFIC TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 42. BRAZIL TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 43. SAUDI ARABIA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 44. UAE TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 45. SOUTH AFRICA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 46. REST OF LAMEA TRAUMATIC BRAIN INJURIES ASSESSMENT MARKET,2021-2031($MILLION)
  • FIGURE 47. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 48. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 49. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 50. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 51. COMPETITIVE DASHBOARD
  • FIGURE 52. COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 53. TOP PLAYER POSITIONING, 2021
  • FIGURE 54. BRAINSCOPE COMPANY INC..: NET SALES ($MILLION)
  • FIGURE 55. NOVASIGNAL CORPORATION.: NET SALES ($MILLION)
  • FIGURE 56. INTEGRA LIFESCIENCES HOLDINGS CORPORATION.: NET SALES ($MILLION)
  • FIGURE 57. NATUS MEDICAL INCORPORATED.: NET SALES ($MILLION)
  • FIGURE 58. BOSTON SCIENTIFIC CORPORATION.: NET SALES ($MILLION)
  • FIGURE 59. KONINKLIJKE PHILIPS N.V..: NET SALES ($MILLION)
  • FIGURE 60. BIODIRECTION, INC..: NET SALES ($MILLION)
  • FIGURE 61. NIHON KOHDEN CORP..: NET SALES ($MILLION)
  • FIGURE 62. RAUMEDIC AG.: NET SALES ($MILLION)
  • FIGURE 63. COMPUMEDICS LTD..: NET SALES ($MILLION)